30,452 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by HTLF Bank

HTLF Bank acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 30,452 shares of the medical research company’s stock, valued at approximately $8,771,000. Amgen makes up 1.0% of HTLF Bank’s investment portfolio, making the stock its 21st biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its stake in shares of Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after purchasing an additional 7,532,031 shares during the last quarter. Norges Bank acquired a new position in Amgen during the 4th quarter worth about $1,351,778,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Amgen by 158.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after purchasing an additional 1,806,456 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $4,589,900,000. Finally, Morgan Stanley lifted its stake in shares of Amgen by 12.9% in the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.9 %

AMGN stock traded up $2.35 on Friday, hitting $265.10. 677,538 shares of the company’s stock were exchanged, compared to its average volume of 2,821,924. The firm has a 50 day moving average price of $277.34 and a two-hundred day moving average price of $281.24. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market cap of $142.07 billion, a P/E ratio of 21.22, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.09 EPS. As a group, equities research analysts expect that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.39%. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Analysts Set New Price Targets

A number of analysts recently commented on AMGN shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Truist Financial reiterated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, Raymond James initiated coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.